<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: following cautionary", fill: "#b87333"},
{source: "2: following cautionary", target: "2: uncertainties relevant", fill: "#b87333"},
{source: "2: uncertainties relevant", target: "2: individually", fill: "#b87333"},
{source: "2: individually", target: "2: aggregate could", fill: "#b87333"},
{source: "2: aggregate could", target: "2: adverse impact on", fill: "#b87333"},
{source: "2: adverse impact on", target: "2: operations", fill: "#b87333"},
{source: "2: operations", target: "2: financial condition", fill: "#b87333"},
{source: "2: financial condition", target: "2: differ materially from", fill: "#b87333"},
{source: "2: following cautionary", target: "6: dialysis reprocessing products", fill: "#fff0f5"},
{source: "6: dialysis reprocessing products", target: "6: dialysis centers", fill: "#fff0f5"},
{source: "6: dialysis centers", target: "6: reuse dialyzers which market", fill: "#fff0f5"},
{source: "6: reuse dialyzers which market", target: "6: been decreasing", fill: "#fff0f5"},
{source: "6: been decreasing", target: "6: United States", fill: "#fff0f5"},
{source: "6: dialysis reprocessing products", target: "8: Dialysis ", fill: "#138808"},
{source: "8: Dialysis ", target: "8: United States ", fill: "#138808"},
{source: "8: United States ", target: "8: dialyzers derive", fill: "#138808"},
{source: "8: dialyzers derive", target: "8: economic benefit since", fill: "#138808"},
{source: "8: economic benefit since", target: "8: utilizing dialyzer reuse compared with single use", fill: "#138808"},
{source: "8: utilizing dialyzer reuse compared with single use", target: "8: such dialysis", fill: "#138808"},
{source: "8: such dialysis", target: "8: clinics generally", fill: "#138808"},
{source: "8: clinics generally", target: "8: capitated payment", fill: "#138808"},
{source: "8: capitated payment", target: "8: providing hemodialysis", fill: "#138808"},
{source: "8: Dialysis ", target: "13: Fresenius ", fill: "#3f00ff"},
{source: "13: Fresenius ", target: "13: significant", fill: "#3f00ff"},
{source: "13: Fresenius ", target: "18: consolidation", fill: "#a1caf1"},
{source: "18: consolidation", target: "18: dialysis providers", fill: "#a1caf1"},
{source: "18: dialysis providers", target: "18: greater buying power", fill: "#a1caf1"},
{source: "18: greater buying power", target: "18: customers which", fill: "#a1caf1"},
{source: "18: customers which", target: "18: selling prices", fill: "#a1caf1"},
{source: "18: selling prices", target: "18: dialysis products thereby reducing net sales", fill: "#a1caf1"},
{source: "18: consolidation", target: "21: consolidation", fill: "#fffaf0"},
{source: "21: consolidation", target: "21: dialysis providers", fill: "#fffaf0"},
{source: "21: dialysis providers", target: "21: greater buying power by certain", fill: "#fffaf0"},
{source: "21: greater buying power by certain", target: "21: customers which", fill: "#fffaf0"},
{source: "21: customers which", target: "21: average selling prices", fill: "#fffaf0"},
{source: "21: average selling prices", target: "21: dialysis products thereby reducing", fill: "#fffaf0"},
{source: "21: dialysis products thereby reducing", target: "21: profit margins", fill: "#fffaf0"},
{source: "21: consolidation", target: "70: dependent on", fill: "#efdecd"},
{source: "70: dependent on", target: "70: new businesses", fill: "#efdecd"},
{source: "70: new businesses", target: "70: businesses", fill: "#efdecd"},
{source: "70: dependent on", target: "73: common stock may", fill: "#ffb300"},
{source: "73: common stock may", target: "73: remain at", fill: "#ffb300"},
{source: "73: remain at", target: "73: price at which", fill: "#ffb300"},
{source: "73: price at which", target: "73: consideration", fill: "#ffb300"},
{source: "73: consideration", target: "73: acquisitions without diluting", fill: "#ffb300"},
{source: "73: acquisitions without diluting", target: "73: stockholders", fill: "#ffb300"},
{source: "73: stockholders", target: "73: potential acquisition candidates may", fill: "#ffb300"},
{source: "73: potential acquisition candidates may", target: "73: attractively", fill: "#ffb300"},
{source: "73: common stock may", target: "112: common stock", fill: "#9457eb"},
{source: "112: common stock", target: "112: significant price", fill: "#9457eb"},
{source: "112: significant price", target: "112: volume fluctuations", fill: "#9457eb"},
{source: "112: volume fluctuations", target: "112: been unrelated", fill: "#9457eb"},
{source: "112: common stock", target: "START_HERE", fill: "#9457eb"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Apparel Accessories and Luxury Goods</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kidney_dialysis">Kidney dialysis</a></td>
      <td>In medicine, dialysis (from Greek διάλυσις, dialysis, 'dissolution'; from διά, dia, 'through', and λύσις, lysis, 'loosening or splitting') is the process of removing excess water, solutes, and toxins from the blood in people whose kidneys can no longer perform these functions naturally. This is referred to as renal replacement therapy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Small_business">Small business</a></td>
      <td>Small businesses are  corporations, partnerships, or sole proprietorships which have fewer employees and/or less annual revenue than a regular-sized business or corporation. Businesses are defined as "small" in terms of being able to apply for government support and qualify for preferential tax policy varies depending on the country and industry.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business">Business</a></td>
      <td>Business is the activity of making one's living or making money by producing or buying and selling products (such as goods and services). It is also "any activity or enterprise entered into for profit."Having a business name does not separate the business entity from the owner, which means that the owner of the business is responsible and liable for debts incurred by the business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business-to-business">Business-to-business</a></td>
      <td>Business-to-business (B2B or, in some countries, BtoB) is a situation where one business makes a commercial transaction with another. This typically occurs when:\n\nA business is sourcing materials for their production process for output   (e.g., a food manufacturer purchasing salt), i.e.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_Is_Business">Business Is Business</a></td>
      <td>Business-to-business (B2B or, in some countries, BtoB) is a situation where one business makes a commercial transaction with another. This typically occurs when:\n\nA business is sourcing materials for their production process for output   (e.g., a food manufacturer purchasing salt), i.e.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_Proposal">Business Proposal</a></td>
      <td>Business Proposal (Korean: 사내 맞선; Hanja: 社內맞선; RR: Sanae Matseon; lit. The Office Blind Date) is a South Korean romantic comedy television series based on the webtoon of the same title written by HaeHwa and illustrated by Narak.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_intelligence">Business intelligence</a></td>
      <td>Business intelligence (BI) comprises the strategies and technologies used by enterprises for the data analysis and management of business information. Common functions of business intelligence technologies include reporting, online analytical processing, analytics, dashboard development, data mining, process mining, complex event processing, business performance management, benchmarking, text mining, predictive analytics, and prescriptive analytics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CANTEL MEDICAL CORP      Item 1A                 RISK FACTORS       We are subject to <font color="blue">various risks</font> and <font color="blue">uncertainties</font> relating to or arising out     of the nature of our <font color="blue">businesses</font> and general business, economic, financing,     legal and other factors or <font color="blue">conditions</font> that <font color="blue">may affect us</font></td>
    </tr>
    <tr>
      <td>We provide the     <font color="blue">following cautionary</font> discussion of risks and <font color="blue">uncertainties</font> relevant to our     <font color="blue">businesses</font>,  which we believe are factors that, <font color="blue">individually</font> or in the     aggregate, could have a material and <font color="blue">adverse impact on</font> our business, results     of <font color="blue">operations</font> and <font color="blue">financial condition</font>, or could cause our actual results to     <font color="blue">differ <font color="blue">materially</font> from</font> expected or historical results</td>
    </tr>
    <tr>
      <td>We note these factors     for <font color="blue">investors as permitted by</font> the Private Securities Litigation Reform Act     of  1995</td>
    </tr>
    <tr>
      <td>You should understand that it is not possible to predict or     identify  all  <font color="blue">such factors</font></td>
    </tr>
    <tr>
      <td>Consequently, you should not consider the     following  to  be  a  complete  discussion  of  all <font color="blue">potential risks</font> or     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our market for <font color="blue">dialysis reprocessing products</font> is limited to <font color="blue">dialysis centers</font>     that reuse <font color="blue">dialyzers</font>, which market has <font color="blue">been decreasing</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">dialyzer reprocessing products</font> are limited to <font color="blue">use by centers</font> that choose     to clean, sterilize and reuse <font color="blue">dialyzers</font>, rather then discard the <font color="blue">dialyzers</font>     after  a  <font color="blue">single use</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dialysis </font>centers in the <font color="blue">United States</font> that reuse     <font color="blue">dialyzers</font> derive an <font color="blue">economic benefit since</font> the per-procedure cost is less     when utilizing <font color="blue">dialyzer reuse</font> compared with <font color="blue">single use</font> and <font color="blue">such dialysis</font>     <font color="blue">clinics generally</font> receive a <font color="blue">capitated payment</font> for <font color="blue">providing hemodialysis</font>     treatment</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>current  public  information is not available to     <font color="blue">accurately quantify</font> the number of <font color="blue">dialysis centers</font> currently employing     <font color="blue">dialyzer reuse</font> versus <font color="blue">single use</font>, it is apparent that the market share of     <font color="blue">single use</font> <font color="blue">dialyzers</font> has <font color="blue">been increasing during</font> the <font color="blue">past five years relative</font>     to  reuse <font color="blue">dialyzers</font></td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">approximately</font> 40prca of all dialysis     centers in the <font color="blue">United States</font> currently reuse <font color="blue">dialyzers</font></td>
    </tr>
    <tr>
      <td>This compares to     <font color="blue">approximately</font> 76prca reuse reported by the <font color="blue">Centers for Disease Control </font>in 2001</td>
    </tr>
    <tr>
      <td>The shift from reuse to <font color="blue">single use</font> <font color="blue">dialyzers</font> is due in large part to the     <font color="blue">commitment</font> of Fresenius, the largest dialysis chain in the <font color="blue">United States</font> and     a <font color="blue"><font color="blue">manufacture</font>r</font> of single-use <font color="blue">dialyzers</font>, to convert all of its reuse dialysis     clinics (including newly acquired clinics) to <font color="blue">single use</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>On     March  31, 2006, <font color="blue">Fresenius </font>acquired RCG, a <font color="blue">significant</font> customer of our     dialysis reuse products</td>
    </tr>
    <tr>
      <td>As <font color="blue">Fresenius </font>      20     ______________________________________________________________________       converts  all or <font color="blue">substantially</font> all of the <font color="blue">dialysis clinics</font> of RCG into     single-use <font color="blue">facilities</font>, our <font color="blue">customer base</font> for <font color="blue">dialysis products <font color="blue">will continue</font></font>     to decrease</td>
    </tr>
    <tr>
      <td>This <font color="blue">downward trend</font> has resulted in, and <font color="blue">will continue</font> to     result in, a decrease in revenues and net income in our dialysis segment</td>
    </tr>
    <tr>
      <td>The <font color="blue">continued decrease</font> in <font color="blue">dialyzer reuse</font> in the <font color="blue">United States</font> in favor of     <font color="blue">single use</font> <font color="blue">dialyzers</font> could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>See “Principal Customers,” “—Competition” and “ Management’s Discussion and     <font color="blue">Analysis  </font>of  Financial Condition and Results of Operations–Results of     Operations</td>
    </tr>
    <tr>
      <td>”       The <font color="blue">consolidation</font> of <font color="blue">dialysis providers</font> has resulted in <font color="blue">greater buying power</font>     by certain of our customers, which has caused us to reduce the average     <font color="blue">selling prices</font> of our dialysis products, thereby reducing net sales and     profit  margins</td>
    </tr>
    <tr>
      <td>Such  <font color="blue">consolidation</font> has also resulted in the loss of     dialysate <font color="blue">concentrate</font> sales</td>
    </tr>
    <tr>
      <td>There has been an increasing <font color="blue">consolidation</font> in the <font color="blue">dialysis industry</font>, marked     by the <font color="blue"><font color="blue">acquisition by</font> certain major dialysis chains</font> of <font color="blue">smaller chains</font> and     <font color="blue">in<font color="blue">dependent</font>s</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">consolidation</font> of <font color="blue">dialysis providers</font> has resulted in     <font color="blue">greater buying power</font> by certain of our customers, which has caused us to     reduce the average <font color="blue">selling prices</font> of our dialysis products, thereby reducing     net sales and <font color="blue">profit margins</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">acquisition by</font> DaVita, the second largest     dialysis chain in the <font color="blue">United States</font>, of Gambro US in October 2005 has had     the most <font color="blue">significant</font> adverse effect in this regard</td>
    </tr>
    <tr>
      <td>In addition, the DaVita     and <font color="blue">Fresenius </font><font color="blue">acquisitions</font> have resulted in the loss of low margin dialysate     <font color="blue">concentrate</font>  business since Gambro and <font color="blue">Fresenius </font><font color="blue"><font color="blue">manufacture</font> dialysate</font>     <font color="blue">concentrate</font> themselves</td>
    </tr>
    <tr>
      <td>Consequently, the DaVita and RCG <font color="blue">dialysis centers</font>     have reduced their purchases of dialysate <font color="blue">concentrate</font> from us</td>
    </tr>
    <tr>
      <td>We  recently  commenced  sales and service of our <font color="blue">Medivators </font>endoscope     <font color="blue">reprocessing systems</font> in the <font color="blue">United States</font> on a <font color="blue">direct basis</font></td>
    </tr>
    <tr>
      <td>There can be no     assurance that our <font color="blue">direct sales</font> and <font color="blue">service program will</font> be successful</td>
    </tr>
    <tr>
      <td>On August 2, 2006, we commenced the sale and service of our <font color="blue">Medivators </font>brand     <font color="blue">endoscope reprocessing products</font> and related <font color="blue">accessories</font> and supplies in the     <font color="blue">United States</font> on a <font color="blue">direct basis</font></td>
    </tr>
    <tr>
      <td>Prior to that time, such products were     <font color="blue">distributed</font>  in  that  territory  through  <font color="blue">Olympus  </font>under an exclusive     <font color="blue"><font color="blue">distribution</font> agreement</font></td>
    </tr>
    <tr>
      <td>We decided not to renew the <font color="blue">agreement with</font> <font color="blue">Olympus  </font>   <font color="blue">based on</font> our belief that it would be in our <font color="blue">best long term interests</font> to     establish our own direct hospital-based <font color="blue">distribution</font> system in the United     States</td>
    </tr>
    <tr>
      <td>Our decision to <font color="blue">sell direct</font> has <font color="blue">necessitated</font> the <font color="blue">establishment</font> of     <font color="blue">new field sales</font> and <font color="blue">marketing teams</font> and the <font color="blue">expenditure</font> of <font color="blue">significant</font>     start-up amounts</td>
    </tr>
    <tr>
      <td>There can be no assurance that our <font color="blue">direct sales</font> program     will be successful</td>
    </tr>
    <tr>
      <td>Because a <font color="blue">significant</font> portion of our Dental segment <font color="blue">net sales comes from</font> a     few large customers, any <font color="blue">significant</font> decrease in sales to these customers     <font color="blue">could harm</font> our operating results</td>
    </tr>
    <tr>
      <td>The  <font color="blue">distribution</font>  network  in  the  United  States <font color="blue">dental industry</font> is     <font color="blue">concentrate</font>d, with relatively few <font color="blue">distributors</font> of <font color="blue">consumables <font color="blue">accounting</font></font> for     a <font color="blue">significant</font> share of the <font color="blue">sales volume</font> to dentists</td>
    </tr>
    <tr>
      <td>Accordingly, net sales     and  <font color="blue">profitability</font>  of  our Dental segment are <font color="blue">highly <font color="blue"><font color="blue">dependent</font> on</font></font> its     <font color="blue">relationships with</font> a limited number of large <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td>During fiscal     2006,  the  top  four  customers  of  our Dental segment accounted for     <font color="blue">approximately</font>  48prca of its net sales, with three of <font color="blue">such customers each</font>     <font color="blue">accounting</font> for 10prca or more of such segment’s net sales</td>
    </tr>
    <tr>
      <td>We are likely to     continue to experience a high degree of <font color="blue">customer concentration</font> in this     segment</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">there will</font> not be a loss or reduction in     business from one or more of our <font color="blue">major customers</font></td>
    </tr>
    <tr>
      <td>In addition, we cannot     assure you that net sales from customers that have accounted for <font color="blue">significant</font>     net sales in the past, either <font color="blue">individually</font> or as a group, will reach or     <font color="blue">exceed historical levels</font> in any <font color="blue">future period</font></td>
    </tr>
    <tr>
      <td>Although we do not anticipate     that any of customers of the Dental segment <font color="blue">will account</font> for more than 10prca     of  our  Company-wide <font color="blue">net sales on</font> a <font color="blue">consolidated basis</font>, the loss or a     <font color="blue">significant</font> reduction of business from any of the <font color="blue">major customers</font> of the     Dental segment <font color="blue">could <font color="blue">adversely</font> affect</font>       21     ______________________________________________________________________       our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, because our Dental segment products     are sold through third-party <font color="blue">distributors</font>, and not directly to end users, we     may not be able to control the amount and timing of resources that our     <font color="blue">distributors</font> devote to our products</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">regulation may delay</font> or <font color="blue">prevent new product <font color="blue">introduction</font></font></td>
    </tr>
    <tr>
      <td>Many of our products are subject to regulation by <font color="blue"><font color="blue">government</font>al</font> and private     agencies  in the <font color="blue">United States</font> and abroad, which regulate the testing,     <font color="blue">manufacturing</font>, packaging, labeling, <font color="blue">distribution</font> and marketing of medical     supplies and devices</td>
    </tr>
    <tr>
      <td>Certain <font color="blue">international regulatory bodies also impose</font>     import <font color="blue">restrictions</font>, tariff regulations, duties, and <font color="blue">tax <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>Delays in <font color="blue">agency review</font> can <font color="blue">significant</font>ly delay new product <font color="blue">introduction</font> and     may result in a product becoming “dated” or losing its <font color="blue">market opportunity</font>     before it can be introduced</td>
    </tr>
    <tr>
      <td>The FDA and other <font color="blue">agency <font color="blue">clearances</font> generally</font>     are required before we can <font color="blue">market <font color="blue">new products</font></font> in the <font color="blue">United States</font> or make     <font color="blue">significant</font> changes to existing products</td>
    </tr>
    <tr>
      <td>The FDA also has the authority to     require a recall or <font color="blue">modification</font> of products in the event of a defect</td>
    </tr>
    <tr>
      <td>The     process of obtaining <font color="blue">marketing <font color="blue">clearances</font></font> and <font color="blue">approvals from regulatory</font>     agencies for <font color="blue">new products</font> can be time consuming and expensive</td>
    </tr>
    <tr>
      <td>There is no     assurance that <font color="blue">clearances</font> or <font color="blue">approvals will</font> be granted or that <font color="blue">agency review</font>     will  not  involve  delays  that <font color="blue">would <font color="blue">adversely</font> affect</font> our ability to     <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Federal, state and <font color="blue">foreign regulations</font> regarding the <font color="blue">manufacture</font> and sale of     our products are subject to change</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> what impact, if any,     such  changes might have on our business</td>
    </tr>
    <tr>
      <td>In addition, there can be no     assurance that regulation of our <font color="blue">products will</font> not become more <font color="blue">restrictive</font>     in  the future and that any <font color="blue">such <font color="blue">development</font> would</font> not have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>For a more detailed discussion on <font color="blue">government</font>     regulation and related risks, see “—<font color="blue">Government </font>Regulation</td>
    </tr>
    <tr>
      <td>”       Customer <font color="blue">acceptance</font> of our products is <font color="blue"><font color="blue">dependent</font> on</font> our ability to meet     changing <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Customer  </font><font color="blue">acceptance</font> of our products is <font color="blue">significant</font>ly <font color="blue"><font color="blue">dependent</font> on</font> our     ability  to  <font color="blue">offer products</font> that meet the changing <font color="blue">requirements</font> of our     customers, including hospitals, industrial laboratories, doctors, dentists,     clinics, <font color="blue">government</font> agencies and <font color="blue">industrial corporations</font></td>
    </tr>
    <tr>
      <td>Any decrease in     the level of customer <font color="blue">acceptance</font> of our <font color="blue">products could</font> have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>We distribute our products in <font color="blue"><font color="blue">highly <font color="blue">competitive</font></font> markets</font></td>
    </tr>
    <tr>
      <td>We  distribute <font color="blue">substantially</font> all of our products in <font color="blue">highly <font color="blue">competitive</font></font>     markets  that  contain  many  products  available  <font color="blue">from nationally</font> and     <font color="blue">internationally</font> recognized <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> have     <font color="blue">significant</font>ly greater financial, technical and human resources than us and     are well-established</td>
    </tr>
    <tr>
      <td>In addition, some companies have developed or may be     expected to develop <font color="blue">technologies</font> or products that <font color="blue">could compete with</font> the     products we <font color="blue">manufacture</font> and distribute or that would render our products     obsolete or <font color="blue">non<font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">competitors</font> may achieve patent     protection, regulatory approval, or <font color="blue">product commercialization</font> that would     limit our ability to <font color="blue">compete with them</font></td>
    </tr>
    <tr>
      <td>Although we believe that we compete     <font color="blue">effectively with</font> all of our present <font color="blue">competitors</font> in our <font color="blue">principal product</font>     groups, there can be no assurance that we <font color="blue">will continue</font> to do so</td>
    </tr>
    <tr>
      <td>These and     other <font color="blue">competitive</font> pressures could have a material adverse effect on our     business</td>
    </tr>
    <tr>
      <td>Currency <font color="blue">fluctuations</font> and trade barriers <font color="blue">could <font color="blue">adversely</font> affect</font> our results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>A  portion  of our dialysis, dental, endoscope reprocessing, and water     <font color="blue">purification</font> and <font color="blue">filtration products</font> are exported and imported to and from     the  Far  East,  Western  Europe and Canada, and our business could be     <font color="blue">materially</font> and <font color="blue">adversely</font> affected by the imposition of trade barriers,     <font color="blue">fluctuations</font>  in  the  rates of exchange of various currencies, tariff     increases and import and export <font color="blue">restrictions</font>,       22     ______________________________________________________________________       <font color="blue">affecting</font> the <font color="blue">United States</font> and Canada</td>
    </tr>
    <tr>
      <td><font color="blue">Our <font color="blue">Canadian </font></font><font color="blue"><font color="blue">subsidiaries</font> purchase</font> a portion of their inventories in United     States dollars and sell a <font color="blue">significant</font> amount of their products in United     States dollars and therefore are exposed to <font color="blue">foreign exchange gains</font> and     <font color="blue">losses upon payment</font> of <font color="blue">such payables</font> and the <font color="blue">collection</font> of <font color="blue">such receivables</font></td>
    </tr>
    <tr>
      <td>Similarly, such <font color="blue">United States</font> <font color="blue"><font color="blue">denominated</font> assets</font> and <font color="blue">liabilities must</font> be     <font color="blue">converted into</font> their functional <font color="blue">Canadian </font>currency when preparing their     financial statements, which results in <font color="blue">foreign exchange gains</font> and losses</td>
    </tr>
    <tr>
      <td>Additionally, the results of <font color="blue">operations</font> of our <font color="blue">Canadian </font><font color="blue">subsidiaries</font> are     <font color="blue">translated from</font> their functional <font color="blue">Canadian </font>currency to <font color="blue">United States</font> dollars     for purposes of preparing our <font color="blue">consolidated financial statements</font></td>
    </tr>
    <tr>
      <td>Therefore,     our continuing <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue">adversely</font> affected by     <font color="blue">fluctuations</font> in the value of the <font color="blue">Canadian </font>dollar against the <font color="blue">United States</font>     dollar or by the imposition of trade barriers, tariff increases or import     and export <font color="blue">restrictions</font> between the <font color="blue">United States</font> and Canada</td>
    </tr>
    <tr>
      <td>Moreover, a     decrease in the value of the <font color="blue">Canadian </font><font color="blue">dollar could</font> result in a <font color="blue">corresponding</font>     reduction  in  the  United  States <font color="blue">dollar value</font> of our assets that are     <font color="blue">denominated</font> in <font color="blue">Canadian </font>dollars</td>
    </tr>
    <tr>
      <td>Our growth may be <font color="blue"><font color="blue">dependent</font> on</font> acquiring <font color="blue">new <font color="blue">businesses</font></font>       We intend to grow, in part, by acquiring <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>The success of this     <font color="blue">strategy depends upon several factors</font>, including:       ·                  our ability to identify and acquire <font color="blue">businesses</font>;       ·                  our ability to integrate acquired <font color="blue">operations</font>, personnel,     products and <font color="blue">technologies</font> into our <font color="blue">organization effectively</font>;       ·                  our ability to retain and <font color="blue">motivate <font color="blue">key personnel</font></font> and to     retain the customers of acquired companies; and       ·                  financing for our <font color="blue">acquisitions</font> may not be <font color="blue">available on</font>     terms we find acceptable</td>
    </tr>
    <tr>
      <td>In  addition,  we  have  used  our  <font color="blue">stock as partial <font color="blue">consideration</font></font> for     <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">common stock</font> may</font> not <font color="blue">remain at</font> a <font color="blue">price at which</font> it can be     used  as  <font color="blue">consideration</font> for <font color="blue">acquisitions</font> without diluting our existing     <font color="blue">stockholders</font>, and <font color="blue">potential acquisition candidates may</font> not view our stock     <font color="blue">attractively</font></td>
    </tr>
    <tr>
      <td>We also may not be able to sustain the rates of growth that we     have experienced in the past, whether by acquiring <font color="blue">businesses</font> or otherwise</td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">businesses</font> are heavily reliant on certain raw materials</td>
    </tr>
    <tr>
      <td>Although there is a <font color="blue">diversity</font> of products produced by our dental segment,     many of them are made <font color="blue">from paper pulp</font> and resin</td>
    </tr>
    <tr>
      <td>In addition, many of our     <font color="blue">products utilize plastic</font> or <font color="blue">stainless steel</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">therefore exposed</font> to     <font color="blue">rising raw</font> material <font color="blue">prices with no guarantees</font> that <font color="blue">such increases</font> in costs     can be <font color="blue">passed along</font> to our customers</td>
    </tr>
    <tr>
      <td>As a result of damage caused by recent <font color="blue">Hurricane Katrina and Hurricane Rita     </font>to many resin suppliers there was a shortage of material in the market for     several months during fiscal 2006</td>
    </tr>
    <tr>
      <td>However, since we had <font color="blue">sufficient resin</font>     inventory to meet our <font color="blue">requirements</font> we were not <font color="blue">adversely</font> affected by the     <font color="blue">market shortage</font></td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       Because we operate in <font color="blue">international markets</font>, we are subject to political and     <font color="blue">economic risks</font> that we do not face in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We operate in a <font color="blue">global market</font></td>
    </tr>
    <tr>
      <td>Global <font color="blue">operations</font> are subject to risks,     including political and economic instability, general economic <font color="blue">conditions</font>,     imposition of <font color="blue">government</font> controls, the need to <font color="blue">comply with</font> a wide variety of     foreign and <font color="blue">United States</font> export laws, trade <font color="blue">restrictions</font>, and the greater     <font color="blue">difficulty</font> of <font color="blue">administering</font> business overseas</td>
    </tr>
    <tr>
      <td>The markets for many of our products are subject to changing <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The markets for many products we sell, particularly endoscope reprocessing     equipment, are subject to changing <font color="blue">technology</font>, new product <font color="blue">introduction</font>s and     <font color="blue">product <font color="blue">enhancement</font>s</font>, and <font color="blue">evolving industry standards</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">introduction</font> or     <font color="blue">enhancement</font> of products embodying new <font color="blue">technology</font> or the emergence of new     <font color="blue">industry standards could</font> render <font color="blue">existing products obsolete</font> or result in     short <font color="blue">product life cycles</font></td>
    </tr>
    <tr>
      <td>Accordingly, our ability to compete is in part     <font color="blue">dependent</font>  on  our  ability to <font color="blue">continually offer enhanced</font> and improved     products</td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">product liability</font> claims resulting from the use of     products we sell and distribute</td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">product liability</font> claims resulting from the products we     sell and distribute</td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">general liability insurance</font> that includes     <font color="blue">product liability</font> coverage, which we believe is adequate for our <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>However, there can be no assurance that <font color="blue">insurance coverage</font> for these risks     <font color="blue">will continue</font> to be available or, if available, that it will be sufficient     to  cover  potential claims or that the <font color="blue">present level</font> of <font color="blue">coverage will</font>     continue to be <font color="blue">available at</font> a <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>A partially or <font color="blue">completely</font>     <font color="blue">uninsured successful</font> claim <font color="blue">against us could</font> have a material adverse effect     on us</td>
    </tr>
    <tr>
      <td>We use <font color="blue">chemicals</font> and other <font color="blue">regulated substances</font> in the <font color="blue">manufacturing</font> of our     products</td>
    </tr>
    <tr>
      <td>In the ordinary course of certain of our <font color="blue">manufacturing</font> processes, we use     various <font color="blue">chemicals</font> and other <font color="blue">regulated substances</font></td>
    </tr>
    <tr>
      <td>Although we are not aware     of any material claims involving violation of <font color="blue">environmental</font> or <font color="blue">occupational</font>     health and <font color="blue">safety laws</font> or regulations, there can be no assurance that such a     claim may not arise in the future, which could have a material adverse     effect on us</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on intellectual property</font> and <font color="blue"><font color="blue">proprietary</font> rights</font> to maintain our     <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>We rely heavily on <font color="blue">proprietary</font> <font color="blue">technology</font> that we <font color="blue">protect primarily through</font>     licensing arrangements, patents, <font color="blue">trade secrets</font>, and <font color="blue">proprietary</font> know-how</td>
    </tr>
    <tr>
      <td>There can be no assurance that any pending or <font color="blue">future patent applications</font>     will be granted or that any current or future patents, regardless of whether     we  are  an owner or a licensee of the patent, will not be challenged,     rendered unenforceable, invalidated, or <font color="blue">circumvented</font> or that the <font color="blue">rights will</font>     provide a <font color="blue">competitive</font> advantage to us</td>
    </tr>
    <tr>
      <td>There can also be no assurance that     our <font color="blue">trade secrets</font> or non-disclosure agreements will provide meaningful     protection of our <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>There can also be no assurance     that others will not in<font color="blue">dependent</font>ly develop similar <font color="blue">technologies</font> or duplicate     any <font color="blue">technology</font> developed by us or that our <font color="blue">technology</font> will not <font color="blue">infringe upon</font>     patents or other rights owned by others</td>
    </tr>
    <tr>
      <td>If we are unable to retain <font color="blue">key personnel</font>, our business could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent</font> to a <font color="blue">significant</font> degree upon the efforts of key     members of our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Although several <font color="blue">key personnel</font> are parties to     employment agreements, such agreements <font color="blue">cannot assure</font> the <font color="blue">continued services</font>     of <font color="blue">such personnel</font>, and the loss or <font color="blue">unavailability</font> of any of them could have     a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>James P     Reilly, our President and Chief Executive Officer, has advised our <font color="blue">Board     </font>that he <font color="blue">will retire upon</font> the expiration of his <font color="blue">employment agreement on</font> <font color="blue">July     </font>31, 2007</td>
    </tr>
    <tr>
      <td>Reilly but there can be no assurance that we <font color="blue">will attract</font>     and hire a <font color="blue">qualified candidate</font> in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>In addition, our success     depends in large part on our ability to attract and retain <font color="blue">highly qualified</font>     scientific, technical, sales, marketing and other personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for     <font color="blue">such personnel</font> is intense and there can be no assurance that we will be able     to  attract and retain the personnel <font color="blue">necessary</font> for the <font color="blue">development</font> and     operation of our <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Our stock price has <font color="blue">been volatile</font> and may experience continued <font color="blue">significant</font>     price and volume <font color="blue">fluctuations</font> in the future that <font color="blue">could reduce</font> the value of     <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>The  market  for  our <font color="blue">common stock</font> has, from time to time, experienced     <font color="blue">significant</font> price and volume <font color="blue">fluctuations</font> that may have <font color="blue">been unrelated</font> to     our operating performance</td>
    </tr>
    <tr>
      <td>Factors <font color="blue">such as announcements</font> of <font color="blue">variations</font> in     our <font color="blue">quarterly financial</font> results and new business <font color="blue">development</font>s could also     cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to fluctuate <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Future issuances of our <font color="blue"><font color="blue">common stock</font> may</font> affect the <font color="blue">market price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue"><font color="blue">additional</font> shares</font> of our <font color="blue"><font color="blue">common stock</font> may</font> <font color="blue">materially</font> and     <font color="blue">adversely</font>  affect  the  per share <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In     addition,  if we issue <font color="blue"><font color="blue">additional</font> shares</font> of our <font color="blue">common stock</font>, existing     holders of our <font color="blue"><font color="blue">common stock</font> may</font> experience dilution, and that <font color="blue">dilution may</font>     be substantial</td>
    </tr>
    <tr>
      <td><font color="blue">Issuances </font>or sales of substantial numbers of <font color="blue">additional</font>     shares of <font color="blue">common stock</font>, including in <font color="blue">connection</font> with future <font color="blue">acquisitions</font>, if     any, or the <font color="blue">perception</font> that <font color="blue">such issuances</font> or <font color="blue">sales could</font> occur, may cause     prevailing <font color="blue">market price</font>s for our <font color="blue">common stock</font> to decline</td>
    </tr>
  </tbody>
</table>